Fatal non-cardiogenic pulmonary oedema after intravenous non-ionic radiographic contrast.

Lancet

Accident and Emergency Department, Horton Hospital, OX16 9AL, Banbury, UK.

Published: March 2002

Life-threatening reactions to radiographic contrast media are rare. We describe a case of fatal non-cardiogenic pulmonary oedema, after use of iopamidol, a widely used, low osmolar, non-ionic, radiographic contrast medium. A woman with a history of bladder tumour who had haematuria was referred for an intravenous urogram. After intravenous injection of 100 mL iopamidol, the woman became short of breath, and a chest radiograph showed severe pulmonary oedema. She was treated but subsequently died. The pathogenesis of contrast-induced, non-cardiogenic pulmonary oedema is unclear, and treatment differs from that for cardiogenic pulmonary oedema.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0140-6736(02)08068-6DOI Listing

Publication Analysis

Top Keywords

pulmonary oedema
20
non-cardiogenic pulmonary
12
radiographic contrast
12
fatal non-cardiogenic
8
non-ionic radiographic
8
pulmonary
5
oedema
5
oedema intravenous
4
intravenous non-ionic
4
contrast life-threatening
4

Similar Publications

Acute lung injury i.e. ALI and its serious form acute respiratory distress syndrome (ARDS) are incurable medical conditions associated with significant global mortality and morbidity.

View Article and Find Full Text PDF

Aneurysmal Subarachnoid Hemorrhage (aSAH), resulting from ruptured aneurysms, is a major contributor to stroke-related mortality and morbidity. Despite advances in healthcare, aSAH remains severe and often leads to complications such as cerebral vasospasm (CV), cerebral infarction, and delayed ischemic neurological deficits (DIND). Clazosentan, an endothelin receptor antagonist, has demonstrated potential in alleviating vasospasm and its associated outcomes, although evidence of its efficacy remains unclear.

View Article and Find Full Text PDF

Cytokine profile of bronchoalveolar lavage in patients with and without checkpoint inhibitor pneumonitis.

Cancer Immunol Immunother

January 2025

Division of Pulmonary, Critical Care, and Sleep Medicine, The Ohio State University Wexner Medical Center, 241 W 11th Ave, Suite 5000, Columbus, OH, 43201, USA.

Background: Checkpoint inhibitor pneumonitis (CIP) that develops following immune checkpoint inhibitor (ICI) treatment can be difficult to distinguish from other common etiologies of lung inflammation in cancer patients. Here, we evaluate the bronchoalveolar lavage fluid (BAL) for potential biomarkers specific to CIP.

Methods: We conducted a retrospective study of patients who underwent standard of care bronchoscopy to compare the cytokines of interest between patients with and without CIP and with and without immune-mediated pulmonary diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!